Articles tagged "Post-transplant malignancy"

2019 American Transplant Congress
Impact of Revised Policy for Hepatocellular Carcinoma MELD Exception Points on Recurrence after Liver Transplantation
P. Le¹, L. McClelland¹, K. Knapp¹, T. Xu¹, S. Pelletier²
¹University of Virginia, Charlottesville, VA, ²Surgery, University of Virginia, Charlottesville, VA
*Purpose: On October 8, 2015, a revised liver policy regarding HCC exception scores was implemented with the intention to create a better balance in transplant…
2019 American Transplant Congress
Screening for Renal Cell Masses in Kidney Transplant
H. E. Fernandez, D. Tsapepas, D. J. Cohen, M. Sumit, L. E. Ratner
Columbia University MC, New York, NY
*Purpose: End-stage renal disease (ESRD) is a risk factor for development of acquired cystic kidney disease (ACKD) with the incidence of ACKD rising from 90%…
2019 American Transplant Congress
Impact of Everolimus on Secondary Nonmelanoma Skin Cancer Prevention in Solid Organ Transplant Recipients
B. Clark¹, D. D. Ramirez¹, A. Carlson¹, B. Sirandas¹, C. Truax¹, L. Smith¹, I. Hall²
¹Solid Organ Transplant, University of Utah Health, Salt Lake City, UT, ²Nephrology and Hypertension, University of Utah Health, Salt Lake City, UT
*Purpose: Over half of solid organ transplant recipients (SOTR) develop nonmelanoma skin cancers (NMSC) and up to 80% experience recurrence. Many immunosuppressive drugs are known…
2019 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders after Living-Donor Liver Transplantation: A Retrospective Cohort Study in 1,900 Cases of Single Center Experience
T. Tajima¹, K. Hata¹, H. Haga², M. Nishikori³, J. Kusakabe¹, I. Tamaki¹, T. Ito¹, T. Kaido¹, A. Takaori-Kondo³, S. Uemoto¹
¹Div. of HBP Surgery and Transplantation, Dept. of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Dept. of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan, ³Dept. of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
*Purpose: Post-transplant lymphoproliferative disorders (PTLD) is relatively rare but the most common, life-threatening neoplasms after organ transplantation. Because of their heterogeneity from benign to malignant…
2019 American Transplant Congress
Incidence and Mortality of Renal Cell Carcinoma after Kidney Transplantation: A Meta-Analysis
A. Chewcharat¹, C. Thongprayoon², B. Boonpheng³, A. Torres-Ortiz⁴, M. A Mao², N. J Khoury⁵, W. Cheungpasitporn⁴
¹Harvard T.H. Chan, Boston, MA, ²Mayo Clinic, Rochester, MN, ³East Tennessee State University, Johnson City, TN, ⁴University of Mississippi Medical Center, Jackson, MS, ⁵Henry Ford Hospital, Detroit, MI
*Purpose: The incidence and mortality of renal cell carcinoma (RCC) after kidney transplantation (KTx) remain unclear. This study's aims were 1) to investigate the pooled…
2018 American Transplant Congress
Decreased Post Heart Transplant Survival with Epstein-Barr Virus Mismatch in the Current Era
M. Kittleson, J. Patel, E. Kransdorf, S. Dimbil, R. Levine, S. Mersola, D. Geft, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Epstein-Barr virus (EBV) has been implicated in a multitude of cancers, including B-cell lymphoma, Burkitt's lymphoma, CNS lymphoma, gastric cancer and nasopharyngeal carcinoma. Previous…
2018 American Transplant Congress
Development of an Expert Consensus Guideline for Skin Cancer Screening in Solid Organ Transplant Recipients
L. Crow,¹ S. Arron,¹ C. Chung,² A. Jambusaria-Pahlajani,³ S. Lowenstein,¹ On behalf of the Transplant Skin Cancer Network.
¹Dermatology, University of California San Francisco, San Francisco, CA; ²Dermatology, Drexel Medicine, Philadelphia, PA; ³Dermatology, Baylor, Scott & White Health, Round Rock, TX.
Importance Skin cancer is the most common malignancy affecting solid organ transplant recipients (SOTR). Transplant recipients have a significantly increased risk for developing both melanoma…
2018 American Transplant Congress
Decreased Expression of Pro-Carcinogenic Genes Following Tacrolimus to Sirolimus Conversion in Liver Transplant Recipients
M. Bhat,¹ E. Pasini,¹ C. Baciu,¹ S. Kurian,² J. Levitsky.³
¹Multi Organ Transplant Program, University Health Network, Toronto, Canada; ²Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA; ³Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University, Chicago.
Long-term survival post-transplant is significantly impacted by malignancy. mTOR-inhibitors (mTORis) have anti-neoplastic properties and are associated with a decreased incidence of certain malignancies compared to…
2018 American Transplant Congress
Immunosuppression Does Not Affect Adverse Pathological Outcomes in Men Who Underwent Radical Prostatectomy
M. Eltemamy, A. Elshafei, Y. Nyame, A. Crane, A. Wee, V. Krishnamurthi, E. Klein, S. Jones.
Cleveland Clinic, Cleveland.
Introduction: The impact of imuunosuppression (IS) on biological aggressiveness of cancer prostate (PCa) is unclear. We aim to assess the adverse pathological (AP) outcomes in…
2018 American Transplant Congress
Y-Adapter Mediated Next Gen Sequencing of BKPyV from Archived FFPE Tissue
E. Harake,¹ W. Wu,² J. Opp,² E. Farkash.¹
¹Pathology, Michigan Medicine, Ann Arbor; ²Michigan Medicine, Ann Arbor.
Background: In a subset of renal transplant recipients with urothelial carcinoma, tumor cells show universal expression of BK Polyomavirus (BKPyV) proteins, a hallmark of oncoviruses.…